Infigratinib, a pan-FGFR1/2/3 inhibitor, showed proof-of-concept activity in an FGFR3-driven murine model of dwarfism (28, 29) and subsequently entered clinical trials in children with ACH (30). The gene discussed is FGFR3; the disease is achondroplasia.